Skip to main content

Day: November 8, 2023

Optiva Inc. Reports Third Quarter 2023 Financial Results

All amounts are stated in United States dollars unless otherwise indicatedRevenue of $11.7 million Optiva selected by three new customers Total Contract Value (“TCV”)1 bookings of $13.6 million Gross margin of 61% Adjusted EBITDA1 loss of $0.8 million Adjusted EPS1 loss of ($0.76) $21.7 million of cashTORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Optiva Inc. (“Optiva” or “the Company”) (TSX:OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today released its third quarter financial results for the three-month period ended September 30, 2023. During the third quarter, Optiva was selected by three new customers and one additional customer shortly after the quarter ended, totaling five new customers year to date. These new logos are a testament...

Continue reading

Genco Shipping & Trading Limited Announces Q3 2023 Financial Results

Declares Dividend of $0.15 per share for Q3 2023, Genco’s 17th Consecutive Quarterly Dividend $500 Million Revolving Credit Facility Expected to Significantly Increase Borrowing Capacity & Enhance Financial Flexibility Agrees to Acquire High Specification Scrubber-Fitted Capesize Vessel NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today reported its financial results for the three months and nine months ended September 30, 2023. Third Quarter 2023 and Year-to-Date HighlightsDividend: Declared a $0.15 per share dividend for Q3 202317th consecutive quarterly payout Cumulative dividends of $4.745 per share or 36% of our share price1 Q3 2023 dividend...

Continue reading

Canoe EIT Income Fund Announces November 2023 Monthly Distribution and Quarterly Distribution on Preferred Units

CALGARY, Alberta, Nov. 08, 2023 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the November 2023 monthly distribution of $0.10 per unit. Additionally, the Fund announces a quarterly distribution for preferred units. Cumulative Redeemable Series 1 (EIT.PR.A) and Series 2 Preferred (EIT.PR.B) unitholders will receive a distribution of $0.30 per unit. The distribution will be paid on December 15, 2023 to unitholders of record on November 22, 2023. The ex-distribution date for this distribution is November 21, 2023. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under...

Continue reading

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.  Business UpdateFor the third quarter ended September 30, 2023, scPharmaceuticals reports:Net FUROSCIX revenue of $3.8 million 1,579 total FUROSCIX prescriptions written877 FUROSCIX prescriptions filled 442...

Continue reading

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022 Installed base of Saphyr® systems totaled 301 as of September 30, 2023, which represents a 39% increase over the number of systems installed as of September 30, 2022 Sold 6,176 nanochannel array flowcells in Q3 2023, which represents a 55% increase over the number of flowcells sold in Q3 2022 Completed an $80.0 million registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Conference call today, November 8th, 2023, at 4:30 PM ETSAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End of Q3 2023Completed an $80.0 million registered offering and concurrent...

Continue reading

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 iPSC-derived CAR T-cell Product Platform Expanded into Autoimmunity; IND Application Cleared by FDA for FT819 CD19-targeted 1XX CAR T-cell Program for Systemic Lupus Erythematosus $350 Million in Cash, Cash Equivalents, and Investments to Support Runway into 2H25 SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

Continue reading

Acutus Medical Reports Third Quarter 2023 Financial Results

CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023. Recent Highlights:Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to Medtronic Registered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expense management Announced strategic realignment of resources and corporate restructuring with the objective of optimizing financial position and maximizing free cash flowThird Quarter 2023 Financial ResultsRevenue was $5.2 million for the third quarter of 2023, an increase of 44% compared to $3.6 million for the third quarter of 2022. The...

Continue reading

HealthEquity Sets Date to Announce Third Quarter Results

DRAPER, Utah , Nov. 08, 2023 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) custodian, today announced plans to release its third quarter of fiscal 2024 financial results following the close of regular stock market trading hours on Tuesday, December 5, 2023. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, December 5, 2023, at 4:30 p.m. ET during which management will review the Company’s third quarter results. HealthEquity Third Quarter Fiscal Year 2024 Results Conference CallDate: December 5, 2023Time: 4:30 p.m. Eastern Time / 2:30 p.m. Mountain TimeDial-In: 1-833-630-1956 (US and Canada) 1-412-317-1837 (International)Conference ID: HealthEquity, Inc. callWebcast: ir.healthequity.comA...

Continue reading

NuCana to Present at the Jefferies London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) — NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 14, 2023Time: 8:00 AM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company’s website at www.nucana.com. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more...

Continue reading

Duolingo Reports 63% DAU Growth and 43% Revenue Growth in Third Quarter 2023; Raises Full Year Guidance

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) — Duolingo, Inc. (NASDAQ: DUOL), the world’s leading mobile learning platform, announced results for the third quarter ended September 30, 2023 in a shareholder letter that is posted at investors.duolingo.com. “We exceeded our own high expectations this quarter, accelerating user growth and delivering impressive bookings and revenue growth,” said Luis von Ahn, Co-Founder and CEO of Duolingo. “Last month, we announced an important strategic shift toward becoming a multi-subject product, with our Math and Music courses being added to the flagship Duolingo app. We believe this offers great value to our users, and can unlock benefit to us over time as we can apply the things that make our language app fun, engaging, and effective to these new courses.” Third Quarter 2023 HighlightsTotal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.